Early Diagnosis of Kidney Damage Associated With Tobacco Use
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03850756|
Recruitment Status : Completed
First Posted : February 22, 2019
Last Update Posted : July 29, 2022
|First Submitted Date||December 27, 2018|
|First Posted Date||February 22, 2019|
|Last Update Posted Date||July 29, 2022|
|Actual Study Start Date||March 4, 2019|
|Actual Primary Completion Date||April 1, 2022 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures
|Original Primary Outcome Measures
|Current Secondary Outcome Measures
|Original Secondary Outcome Measures
|Current Other Pre-specified Outcome Measures||Not Provided|
|Original Other Pre-specified Outcome Measures||Not Provided|
|Brief Title||Early Diagnosis of Kidney Damage Associated With Tobacco Use|
|Official Title||New Diagnostic System for the Early Detection of Chronic Renal Damage Associated to Tobacco Consumption: Preventive and Personalized Application|
Tobacco consumption is associated with the appearance of several pathologies, the best known are Chronic Obstructive Pulmonary Disease, several types of cancer and cardiovascular diseases. However, the association between tobacco and kidney damage is not well defined. Some studies suggest that smoking favors progression to chronic kidney disease (CKD). CKD does not have pharmacological treatment and the only clinical strategies useful so far are dialysis or kidney transplantation. Therefore, knowing if tobacco is involved in this disease is a very relevant fact, since it is a modifiable factor. Of all the risk factors associated with the onset and progression of kidney disease is the only one that can be avoid or eliminated. Therefore quitting smoking could help reduce the incidence of this pathology.
In this project, 3 main objectives were proposed:
According to the WHO, smoking is the main cause of preventable disease and death, being a known risk factor for the development of cancer, respiratory diseases, cardiovascular diseases, etc. Despite the fact that the first associations between smoking and kidney disease date back to the beginning of the last century, up to the present time, evidence has been scarce and inconclusive in the population without risk factors associated with kidney disease.
The increase in the worldwide prevalence of chronic kidney disease and the notable increase in the incidence of patients reaching the final stage of the same, have alerted health systems and have determined that nephrologists focus more on the identification of potentially modifiable prevention factors. Chronic kidney disease has a very high social and economic cost (almost 10% of the affected population and 3% of total health expenditure), which requires coordinated criteria among health professionals to ensure the best levels of quality in prevention, diagnosis and treatment. In this sense, it is recognized that the key to preventive success is a very early diagnosis that allows intervention when the renal functional reserve has not yet been exhausted and, therefore, the excretory function is not yet compromised. In the clinic, one of the most used tools in the diagnosis of kidney damage is based on the detection in the blood of products of metabolism (creatinine, urea, etc.) that begin to accumulate once the renal excretory capacity begins to decrease. However, when the increase in serum urea and creatinine levels is observed, more than 70% of renal function has been lost. Thus, current trends in diagnosis seek to find sensitive markers, specific, and easy to quantify, that detect incipient pathophysiological events produced in early stages, when the damage is less widespread.
To evaluate in depth the association between tobacco consumption and kidney damage, as well as the capacity to recover renal function after cessation of consumption, a longitudinal prospective observational study is proposed. Participants will be informed of the objectives of the project and its benefits both verbally and in writing and will have to sign an informed consent in accordance with the Declaration of Helsinki and the WHO standards for observational studies. Patients will be included completely anonymously and their data will be treated confidentially according to the current data protection legislation. Patients may withdraw freely from the study at any time.
In this study, three main objectives have been proposed:
OBJECTIVE 1: To detect subclinical renal damage in smokers through a battery of early markers.
Previously it was carried out a pilot study with 200 patients in order to check if certain early biomarkers of kidney damage, were able to evidence a possible early lesion not detectable with the usual techniques. The results showed an association between tobacco and kidney damage that needs to be confirmed with a greater number of patients. Based on these results, a new study is considered more robust in terms of the number of patients and broader in terms of the determined markers. It is estimated to include a total of 500 patients (125 per group). The grouping of the same will be based on whether they smoke or not and also be taken into account if they have certain risk factors associated with the onset of kidney damage. Therefore, they will be divided into four groups: 1-No smokers without risk factors, 2-No smokers with risk factors, 3-Smokers without risk factors, 4-Smokers with risk factors.
At the time of inclusion in the study, each patient will obtain the following information: date of collection of the sample; general data (age, sex, drug consumption); anthropometric measurements (body weight, height, body mass index) and analytical biochemistry (plasma creatinine and urea). Information will also be obtained on risk factors for kidney damage (hypertension, diabetes, cardiovascular disease or chronic pain with frequent use of NSAIDs, including the date of diagnosis, the prescribed drugs); tobacco use, the patient will fill out a questionnaire adapted from the WHO MONICA study, which will allow us to classify them as a smoker, non-smoker or ex-smoker and also know the number of cigarettes / cigars consumed per day.
After the recruitment, a urine sample will also be taken in order to analyze the presence of biomarkers of early kidney damage. In addition, the concentration of cotinine in urine (nicotine metabolite) will be evaluated, which will allow to know indirectly the consumption of tobacco in smokers and the absence of tobacco in non-smokers.
OBJECTIVE 2: To study if certain predisposing markers (albumin, and others in patent phase), already identified in previous studies, are able to detect in patients who smoke those who are predisposed to suffer acute kidney damage.
The second strategy proposed in this project raises a new concept of intervention even earlier, before the damage occurs. It has been developed an innovative concept: predisposition to kidney injury. It means that different drugs and renal toxins (in completely subtoxic doses) are capable of predisposing, or making more sensitive to experimental animals to acute kidney damage. The relevance of this situation is that individuals apparently unaffected by the adverse effects of a treatment, or by exposure to toxic substances (such as tobacco) could be exposed to develop acute kidney damage. Associated with this condition it have been identified urinary markers. Their clinical application will allow, not only to detect this predisposition, but to stratify the patients in a preventive and personalized way according to the individual risk of each patient as a result of apparently innocuous pharmacological treatments, or exposure to chemical substances.
To respond to this second objective, a follow-up of 2 years will be carried out to patients in groups 1 and 3, that is, to non-smokers, and to smokers both without risk factors. In this way, the information provided by the markers of kidney damage may be associated with tobacco consumption and not with other causes. In this case, it is estimated that the total number of participants will be 100 per group since it is possible that a percentage of patients will be lost during the follow-up phase. At 24 months, patients will come back to the clinic and deliver a urine sample. In these samples and in the collections in the previous objective (0 months or baseline) the predisposition markers described above will be evaluated. The levels of biomarkers of predisposition at the beginning of the study will be related to renal function in the medium term, evaluated by biomarkers of early damage. In addition, the usual clinical parameters (plasma creatinine, creatinine clearance, plasma urea and proteinuria) will be taken into account.
OBJECTIVE 3: To study whether smoking cessation reduces subclinical renal damage and / or predisposition to acute renal damage.
With this objective, it is proposed to study whether renal parameters and markers are restored once smoking cessation ceases. Which would mean, not only that they are a useful tool in terms of diagnosis, but also an efficient preventive measure.
For this purpose, patients from the "Smoking Unit of the University Assistance Complex of Salamanca (CAUSA)" will be recruited. Those patients who agree to participate in the study will deliver a urine sample at the time of inclusion (time 0 or baseline) and also during follow-up at 3, 6 and 12 months. In these urine samples the markers mentioned in the two previous objectives will be determined. The data provided by the markers of both early injury and predisposition will be useful to analyze the evolution of renal function after the cessation of tobacco use. With this information it well be checked if smoking cessation reduces subclinical renal damage and / or the risk of acute renal damage.
As in Objective 1, after the inclusion of the patient, the following data will be obtained: date of collection of the sample; general data, anthropometric measurements, analytical biochemistry, information about risk factors for kidney damage, date of the diagnosis, prescribed drugs, questionnaire adapted from the WHO MONICA study. Other parameters will also be obtained, such as the concentration of carbon monoxide in exhaled air (measured with a co-oximeter) and the concentration of cotinine in the blood.
COLLECTION OF SAMPLES AND PROCESSING Each patient will be assigned a code, so its identity will only be known by the treating physician. Urine samples will be identified under the established code. Once collected (both those of the Primary Care Center and those of the Smoking Unit), they will be transferred to the CAUSA Sample Bank, where they will be centrifuged, aliquoted and stored at -80 degrees Celsius until they are determined.
ANALYSIS OF URINE SAMPLES All the analytical determinations of this study will be carried out in the laboratories of the "Tera-gnostics of Renal and Cardiovascular Diseases" group of the Bio-sanitary Institute of Salamanca (IBSAL). These determinations will be as follows: proteinuria as a clinical marker of damage by Bradford colorimetric method; early markers of kidney damage by colorimetric kits, ELISA and Western Blot; predisposition markers (in patent phase) by Western Blot, ELISA; Tobacco use marker (cotinine in urine) by ELISA. All urinary concentrations of markers will be corrected by urinary creatinine (colorimetric kit).
STATISTIC ANALYSIS A significance level of 0.05 will be used. The data analysis will be performed with STATA 10 and Statistical Package for the Social Sciences (SPSS) 20.0. Different contrasts will be applied depending on the association that is to be studied in each case, and the type of variables, such as: normality test (Kolmogorov-Smirnov, Shapiro-Wilk), frequency comparison (χ2), correlation test (Pearson, Spearman), comparison of means for independent data (ANOVA and Kruskal-Wallis) and repeated measures ANOVA and Wilcoxon test for paired data. Finally, to study simultaneously datasets with several variables measured for each individual or parameter collected, a Multivariate Analysis will be used, such as: regression analysis, general linear models, binary logistic regression and correspondence analysis.
LIMITATIONS OF THE STUDY Although the study follows all the recommendations for observational studies considered in the STROBE statement (STrengthening the Reporting of OBservational studies in Epidemiology), there is a possibility that there are factors that have not been considered. On the other hand, the included variables are biomarkers of early kidney damage and predisposition to acute renal damage induced by certain renal toxins. It is possible that there are other markers (unknown), that are not being analyzed, and that can predict the kidney damage associated with smoking.
CONCLUSION In short, this project addresses two issues of high concern in the health field, which are smoking and chronic kidney disease. From its conceptual basis, it raises the possibility of finding a diagnostic tool for the early detection of chronic kidney damage associated with tobacco consumption, with a preventive purpose in terms of the development of the disease and in a personalized way regarding the hypersensitivity of each patient. . Account for it with a consortium of researchers and clinicians consisting of: 1) experts in markers of kidney damage, 2) clinicians specialized in lifestyles and cardiovascular risk, 3) specialists in smoking.
|Study Design||Observational Model: Case-Control
Time Perspective: Prospective
|Target Follow-Up Duration||Not Provided|
|Biospecimen||Retention: Samples Without DNA
In this project, only urine samples will be collected. This will be centrifuged, aliquoted and stored at -80 degrees Celsius until its determination.
|Sampling Method||Non-Probability Sample|
|Study Population||This study will be carried out with the general population, specifically patients who attend a Primary Care consultation (Objectives 1 and 2), and people who come to the Smoking Unit to try to stop smoking (Objective 3)|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Original Estimated Enrollment||Same as current|
|Actual Study Completion Date||July 1, 2022|
|Actual Primary Completion Date||April 1, 2022 (Final data collection date for primary outcome measure)|
|Ages||18 Years to 99 Years (Adult, Older Adult)|
|Accepts Healthy Volunteers||Yes|
|Contacts||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries||Spain|
|Removed Location Countries|
|Other Study ID Numbers||BIOTAB|
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||
|IPD Sharing Statement||
|Current Responsible Party||Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León|
|Original Responsible Party||Same as current|
|Current Study Sponsor||Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León|
|Original Study Sponsor||Same as current|
|PRS Account||Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León|
|Verification Date||July 2022|